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Prostate cancer most commonly metastasizes to bone, lung and liver. Omental metastasis of prostate
cancer is extremely rare, with only a few cases reported in the literature, many of which have associated
ascites. We present a case of non-ascitic omental metastasis of prostate cancer without any bone me-
tastases. Furthermore, this patient has had two negative measurements of circulating tumor cells (CTCs)
in the blood, suggesting a non-hematogenous route of metastasis to the omentum.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Peritoneal carcinomatosis secondary to prostate cancer (pCa)
with no further metastases is very rare, with only four reported
cases in the available literature, all presenting with ascites. Port-site
metastasis after minimally invasive urological surgery is similarly
rare despite the widespread use of laparoscopic techniques in the
management of urological malignancies. We report a case of
possible port-site metastasis and subsequent peritoneal carcino-
matosis following robot-assisted radical prostatectomy.Case report
A 60-year-old man presented with an elevated prostate-speciﬁc
antigen (PSA) of 9.5 ng/mL in 2010. Transrectal biopsy of the
prostate revealed Gleason 3 þ 4 prostatic adenocarcinoma. Robotic
prostatectomy was performed at an outside hospital in October
2010 and after surgery, the PSA never became undetectable. The
patient subsequently received adjuvant hormone therapy and
salvage radiation therapy in April 2011. A bone scan performed inark, NJ 07103, USA.
Inc. This is an open access article uOctober 2011 was negative for metastatic disease. In March 2012,
the PSA nadir was 0.02; rising with a doubling time of 3.4months to
reach 5.6 before starting ADT.
Baseline scans in September 2013 were a bone scan negative for
metastatic disease and a CT chest/abdomen/pelvis scan showing a
0.9  1.1 cm indeterminate omental nodule, located on the right
side just proximal to the prostatectomy exit port above the umbi-
licus. In February 2014 he reached a new PSA nadir of 0.4. A repeat
CT scan then showed that the soft tissue nodule in the omentum
had decreased in size from 1.1 cm to 0.8 cmwith the onset of ADT. In
February 2015, PSA was 4.1, bone scan again was without evidence
of metastatic disease, and CT scan showed the omental nodule
increased to 1.4 cmwith a new adjacent subcentimeter nodule. PSA
continued to increasewith a 2.2month doubling time, reaching 11.4
on 5/21/15.
Patient underwent CT-guided omental biopsy in April 2015,
which stained positive for racemase and PSA, consistent with
metastatic poorly differentiated carcinoma of prostatic origin. The
same month a circulating tumor cell (CTC) assay, involving immu-
nomagnetic sample enrichment with ﬂuorescent antibody staining,
showed zero tumor cells in the blood. Repeat bone scan inMay 2015
showed no evidence of metastatic disease to bone and CT chest/
abdomen/pelvic showed the omental nodule that now measured
1.7  1.4 cm in size (Fig. 1).
Patient subsequently underwent a total omentectomy in May
2015. Pathology of the resected omentum showed a 2.5 cm, ﬁrmnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CT scan from May 2015, before total omentectomy, shows the 1.7  1.4 cm
omental nodule (white arrow at center top).
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appearance on the prior biopsy. PSA was 11.8 before surgery and
following surgery, PSA decreased to 1.8 within 1 month. The PSA
continued to rise with a 1.9 month doubling time, reaching 31 in
March 2016. A choline-11 PET/CT scan at that time showed radio-
tracer avid peritoneal nodules and nodules within the prostatic bed.
There were three radiotracer avid lymph nodes: one left external
iliac (2  1.7 mm) and one on the right (4  5 mm), and a left
obturator node (5  7 mm). Circulating tumor cells were measured
in April and May 2016, again showing zero cells. Patient started
abiraterone in May 2016 when his PSAwas 89; PSA fell to 1.0 by end
of July 2016, with tumor nodule dimensions reduced 25%-50%.
Discussion
Prostatic adenocarcinoma metastasizes 35% of the time, with an
overwhelming predilection to involve the bone. The most frequent
organ involved in metastatic pCa is bone (90%). Clinical involve-
ment of visceral sites, such as lung (46%), liver (25%), pleura (21%)
and adrenals (13%), is less common, even in patients with wide-
spread castration-resistant disease.1 Prostatic adenocarcinomawith
metastasis to the peritoneum is extremely rare, evenmore so in the
absence of any bony involvement.
Our case is unique in several ways. First, there are only four
reported cases in the literature of pCa with omentum as its only
metastasis.2e5 None of the previously reported cases have the
frequent imaging and staging of our case. All four cases presented
with gross ascites, suggesting that such presentations of metastatic
pCa likely present late in illness course. Additionally, none of the
previously reported cases presented after a laparoscopic prosta-
tectomy, which raises the possibility of this peritoneal carcinoma-
tosis resulting from port-site metastasis. In our case, the discovery
of peritoneal metastasis approximately 30 months post-op withoutany major abdominal symptoms such as ascites, is unique. The
patient has had several bone scans come back negative for meta-
static disease while his treatment course has been complicated by
isolated metastasis to the omentum. Our case is a case of potential
port-site metastasis without bony metastases, without the pre-
sentation of ascites and without the involvement of other intra-
abdominal structures apart from the omentum.
The mechanism of metastatic pCa to the omentum in the
absence of skeletal metastasis is unclear. Since our patient has had
the circulating tumor cells in his blood measured twice, both times
coming back negative, hematogenous spread of the cancer is highly
unlikely. Kehinde et al3 suggested that the mucinous adenocarci-
noma of the prostate is reported to be characterized by rarity of
bone metastases, lesser degree of response to local radiation ther-
apy and lack of hormone dependence. However, our patient did not
have a mucinous adenocarcinoma and clearly showed response to
ﬁrst line and second line hormonal treatment. The lack of hema-
togenous spread and relative absence of lymphatic involvement,
suggests that the tumor cells traveled directly through the perito-
neum to reach the omentum. Further peritoneal dissemination
could have occurred from the omental port-site metastasis.
Ultimately, the possibility of discovering whether or not seeding
from a port-site metastasis occurred is and will likely remain
unclear. The positive margin after laparoscopic prostatectomy also
suggests that the cancer could have metastasized shortly after the
prostate removal before pelvic radiation 6 months later.
Our patient’s PSA substantial decrease following omentectomy
suggests that omentumwas the ﬁrst site of metastasis. Whether or
not this is a port-site metastasis will likely remain unclear, but what
is deﬁnitive is the fact that we have a case of isolated peritoneal
carcinomatosis without ascites unlikely to have resulted from
hematogenous spread.Conﬂict of interest
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